This week we are very excited to welcome two new lab members, Alex Green and Shade Rodriguez!
New combinations and repurposed antibiotics active against the pandrug-resistant Nevada CRE, NDM-1 strain early release today in AAC
Our latest manuscript: "Synergistic combinations and repurposed antibiotics active against the pandrug-resistant Klebsiella pneumoniae Nevada strain." Antimicrobial Agents and Chemotherapy early release identifies:
Highly synergistic activity of several antimicrobial combinations.
Low apramycin and spectinomycin MIC values.
CDC previously reported that none of 26 antimicrobials they tested were active against the Nevada strain. That made the strain until now pandrug-resistant.
Links to several news articles about this pandrug-resistant strain::
The Atlantic. NPR, NBC, PBS. Forbes
"3 Drug Combinations Appear Effective Against C auris" by Jared Kaltwasser discussed work presented by Thea Brennan-Krohn at ASM Microbe 2019.
Kate, KP, and Thea presented posters at ASM Microbe 2019. Thea not shown.
Our D300 antimicrobial method has made it to the big screen! Caught both JCM AST and AAC pathogen bioprinting.
BIDMC press release on poster presented by postdoctoral fellow, Thea-Brennan Krohn, at the ASM Microbe Meeting in San Francisco this past weekend!
"Using the inkjet technology to dispense uniform samples of C. auris into each of the 96 wells in a standard lab testing plate, Brennan-Krohn tested 10 combinations against 10 strains of C. auris, a painstaking process that would have taken at least 50 hours if done by hand. It took less than two hours in total using the inkjet dispenser for Brennan-Krohn to find three novel combinations of antifungal and antibacterial drugs that demonstrated activity against this insidious new pathogen."
High throughput drug discovery manuscript describing collaborative efforts of Manetsch and Kirby laboratory to identify new CRE therapeutics accepted today!
First author KP Smith. ICCB Screening Center plays pivotal role. More details to follow!
Kirby Lab Blog